Business

Innovent Biologics Shares Surge After Pfizer Deal

Updated 2026-05-29 03:20 UTC 1 source Positive

Innovent Biologics' shares rose 10% following a strategic licensing agreement with Pfizer worth up to $10.5 billion, aimed at developing oncology medicines.

Coverage timeline — 1 article

CNBC

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

2026-05-29 03:10 UTC